Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients

University Hospital, Toulouse50 enrolled

Overview

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Myeloid Leukemia

Interventions

rapamycinDRUG

sirolimus

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent * de novo or secondary LAM (CML excluded) not elligible for intensive chemotherapy. * Previously untreated Exclusion Criteria: * Renal impairment (serum creatinin \>2N) * Hepatic impairment (TGO ou TGP \> 5N), une cholestase (Phosphatases Alcalines or gamma-GT \> 5N),bilirubin \> 3N * Blast crisis CML * Acute Promyelocytic Leukemia.

Locations (3)

Service d'Hématologie, CHU

Angers, France

Service d'Hématologie, Hôpital Jean Minjoz

Besançon, France

Service d'Hématologie CHU Purpan

Toulouse, France

Outcomes

Primary Outcomes

response rate

Secondary Outcomes

tolerability

bioclinical markers of response

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.